John S. Riley

John S. Riley

Auto-generated profile, based on publicly available information

John S. Riley

Center for Fetal Research, Children's Hospital of Philadelphia, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
RPRohan Palanki
Rohan Palanki
JRJohn S. Riley
John S. Riley
SBSourav K. Bose
Sourav K. Bose
VLValerie Luks
Valerie Luks
ADApeksha Dave
Apeksha Dave
WPWilliam H. Peranteau
William H. Peranteau
Monogenic blood diseases are among the most common genetic disorders worldwide. These diseases result in significant pediatric and adult morbidity, and some can result in death prior to birth. Novel ex vivo hematopoietic stem cell (HSC) gene editing therapies hold tremendous promise to alter the therapeutic landscape but are not without potential limitations. In vivo gene editing therapies offer a potentially safer and more accessible treatment for these diseases but are hindered by a lack of delivery vectors targeting HSCs, which reside in the difficult-to-access bone marrow niche. Here, we propose that this biological barrier can be overcome by taking advantage of HSC residence in the easily accessible liver during fetal development. To facilitate the delivery of gene editing cargo to fetal HSCs, we developed an ionizable lipid nanoparticle (LNP) platform targeting the CD45 receptor on the surface of HSCs. After validating that targeted LNPs improved messenger ribonucleic acid (mRNA) delivery to hematopoietic lineage cells via a CD45-specific mechanism in vitro, we demonstrated that this platform mediated safe, potent, and long-term gene modulation of HSCs in vivo in multiple mouse models. We further optimized this LNP platform in vitro to encapsulate and deliver CRISPR-based nucleic acid cargos. Finally, we showed that optimized and targeted LNPs enhanced gene editing at a proof-of-concept locus in fetal HSCs after a single in utero intravenous injection. By targeting HSCs in vivo during fetal development, our Systematically optimized Targeted Editing Machinery (STEM) LNPs may provide a translatable strategy to treat monogenic blood diseases before birth.

16 December 2022 in Experimental Hematology
Verified
Journal Article
Closed access
JRJohn S. Riley
John S. Riley
LMLauren E. McClain
Lauren E. McClain
JSJohn D. Stratigis
John D. Stratigis
BCBarbara E. Coons
Barbara E. Coons
SBSourav K. Bose
Sourav K. Bose
WPWilliam H. Peranteau
William H. Peranteau

28 August 2024 in Blood Advances
Verified
Journal Article
Open access
JRJohn S. Riley
John S. Riley
CBCara L. Berkowitz
Cara L. Berkowitz
VLValerie L. Luks
Valerie L. Luks
ADApeksha Dave
Apeksha Dave
MCMojisola C. Cyril-Olutayo
Mojisola C. Cyril-Olutayo
WPWilliam H Peranteau
William H Peranteau
In utero hematopoietic cell transplantation is an experimental nonmyeloablative therapy with potential applications in hematologic disorders, including sickle cell disease (SCD). Its clinical utility has been limited due to the early acquisition of T-cell immunity beginning at ∼14 weeks gestation, posing significant technical challenges and excluding treatment fetuses evaluated after the first trimester. Using murine neonatal transplantation at 20 days postcoitum (DPC) as a model for late-gestation transplantation (LGT) in humans, we investigated whether immune modulation with anti-CD3 monoclonal antibody (mAb) could achieve donor-specific tolerance and sustained allogeneic engraftment comparable with that of the early-gestation fetal recipient at 14 DPC. In allogeneic wild-type strain combinations, administration of anti-CD3 mAb with transplantation resulted in transient T-cell depletion followed by central tolerance induction confirmed by donor–specific clonal deletion and skin graft tolerance. Normal immune responses to third-party major histocompatibility complex and viral pathogens were preserved, and graft-versus-host disease did not occur. We further demonstrated the successful application of this approach in the Townes mouse model of SCD. These findings confirm the developing fetal T-cell response as a barrier to LGT and support transient T-cell depletion as a safe and effective immunomodulatory strategy to overcome it.

20 June 2023 in Fetal Diagnosis and Therapy
Verified
Journal Article
Closed access
PDF file
JRJohn S. Riley
John S. Riley
JSJohn Schomberg
John Schomberg
AMAditya Mantha
Aditya Mantha
YGYigit S. Guner
Yigit S. Guner
ACAmy Cuevas
Amy Cuevas
PYPeter T. Yu
Peter T. Yu
Introduction: VACTERL is defined as 3 or more of the following congenital defects: vertebral, anorectal, cardiac, tracheoesophageal (TE), renal, and limb. The purpose of this study was to create an easy-to-use assessment tool to help providers counsel expecting families regarding the likelihood of additional anomalies and postnatal outcomes. Methods: Employing the Kids’ Inpatient Database from 2003–2016, neonates (<29 days old) with VACTERL were identified using ICD-9-CM and ICD-10-CM codes. For each unique combination of VACTERL, multivariable logistic regression was used to estimate inpatient mortality, and Poisson regression was used to estimate length-of-stay during the initial hospitalization. Results: The assessment tool used in this study is available at https://choc-trauma.shinyapps.io/VACTERL. 1,886 of 11,813,782 (0.016%) neonates presented with VACTERL. 32% weighed <1,750 g, and 239 (12.7%) died prior to discharge. Associated with mortality were limb anomaly (1.8 [1.01–3.22], p < 0.05), prematurity (1.99 [1.14–3.47], p < 0.02), and weight <1,750 g (2.19 [1.25–3.82], p < 0.01). Median length-of-stay was 14 days (IQR: 7-32). Associated with increased length-of-stay were cardiac defect (1.47 [1.37–1.56], p < 0.001), vertebral anomaly (1.1 [1.05–1.14], p < 0.001), TE fistula (1.73 [1.66–1.81], p < 0.001), anorectal malformation (1.12 [1.07–1.16], p < 0.001), and weight <1,750 g (1.65 [1.57–1.73], p < 0.001). Conclusion: This novel assessment tool may help providers counsel families confronting a VACTERL diagnosis.

30 September 2026 in Journal of Pediatric Surgery Case Reports
Verified
Journal Article
Open access
MBM. Connor Blue
M. Connor Blue
CKCamryn J. Krumbhaar
Camryn J. Krumbhaar
RHRosa Hwang
Rosa Hwang
JRJohn S. Riley
John S. Riley
GNGary W. Nace
Gary W. Nace